About
758
Publications
96,134
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
26,560
Citations
Introduction
Current institution
Publications
Publications (758)
Background and Aim: The human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-20% of breast carcinomas (BC). Patients with inoperable or metastatic BC and low HER2 expression (HER2-low) may benefit from trastuzumab-deruxtecan. The aim of this study was to compare HER2 status with ERBB2-mRNA expression analysis, and to analyze the a...
Background This year, the St. Gallen Confernece was held from March 12th -15th, 2025, with the largest attendance since the pandemic, more than 3.000 participants from over 100 countries. Summary: The conference chairs professionally guided through the program on Early Breast Cancer, featuring abstracts submitted from all over the world. In additio...
Purpose
There is evidence that statins might improve the outcome of patients with breast cancer. The role of statins in patients with early HER2-positive breast cancer is unknown. Therefore, we explored the association between statin use and survival outcomes in early HER2-positive breast cancer patients in the phase III APHINITY trial (adjuvant pe...
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC).
Optimal management of breast cancer requires a multidisciplinary strategy. Each year the interdisciplinary AGO Breast Committee provides updated state-of-the-art recommendations on the prevention, diagnosis and treatment of breast cancer. This update follows a defined algorithm. The most recent and relevant publications are reviewed and the scienti...
Klinische Evidenz wird auf Basis klinischer Studien und der persönlichen Erfahrung interpretiert. Dies kann in einer unterschiedlichen Deutung der Datenlage resultieren. Vor diesem Hintergrund sind Expertenpanels wie das Advanced Breast Cancer Panel, das im November 2023 zum 7. Mal zusammengekommen ist (ABC7), von besonderer Bedeutung. Aktuelle The...
Sexually transmitted infections (STIs) and human papillomavirus (HPV) infections are common among women of reproductive age and can lead to infertility, adverse pregnancy outcomes, neonatal infections and cervical cancer. In countries with limited medical coverage, untreated infections contribute to high morbidity. This study aimed to expand the cu...
The 7th “International Consensus Conference on Advanced Breast Cancer” (ABC) met from 9–12 November 2023 in Lisbon, Portugal. The consensus is organized by a group of experts from different countries and disciplines.
The rationale of the international consensus conference is to standardize the treatment of patients with primarily inoperable, locall...
Purpose
Systemic therapy plays a major part in the cure of patients with early breast cancer (eBC). However, personalized treatment concepts are required to avoid potentially harmful overtreatment. Biomarkers are pivotal for individualized therapy. The Notch signalling pathway is widely considered as a suitable prognostic or predictive marker in eB...
Cervical cancer is the second most commonly diagnosed cancer in women in Ethiopia. However, data are limited on the prevalence of human papillomavirus (HPV) genotypes. Self-sampled vaginal lavages were obtained consecutively from 783 women attending 7 health facilities across Ethiopia. Genotype prevalence was assessed by Multiplex-Papillomavirus-Ge...
The rationale behind the “International Consensus Conference for Advanced Breast Cancer” (ABC) is to standardize the treatment of patients with advanced or metastatic breast cancer worldwide using an evidence-based approach. The aim is also to ensure that patients in all countries receive adequate treatment based on current treatment recommendation...
Clinical evidence is interpreted based on clinical studies and personal experience which can lead to different interpretations of data. This makes the opinions issued by panels of experts such as the Advanced Breast Cancer Panel which convened in November 2023 for the seventh time (ABC7) particularly important. At the conference, current issues aro...
Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is known about the patient selection for this population in clinical practice. Therefore,...
Background
The evaluation of electronic patient-reported outcomes (ePROs) is increasingly being used in clinical studies of patients with cancer and enables structured and standardized data collection in patients’ everyday lives. So far, few studies or analyses have focused on the medical benefit of ePROs for patients.
Objective
The current explor...
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Global Alliance. It provides the main recommendations on how to best manage patients with advanced breast...
[This corrects the article DOI: 10.1055/a-2238-3153.].
The diagnosis of metastasis of breast cancer is frightening news for the patient concerned; the term is associated with the threat to life posed by this disease. It is still true that metastasis cannot be cured but the use of modern substances has now made it possible to significantly prolong life. This brief outline presents the new substances and...
Systemic breast cancer treatment is currently based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperativ...
Introduction:
Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Breast Cancer provides updated state-of-the-art recommendations for early and metastatic breast cancer.
Methods:
The updated evidence-based treatment recommendations...
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2024 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC).
Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is known about the patient selection for this population in clinical practice. Therefore,...
Background:
The "International Consensus Conference for Advanced Breast Cancer" was initiated more than 10 years ago. The rationale was to standardize treatment of advanced breast cancer (ABC) based on available evidence and to ensure that all ABC patients worldwide receive adequate treatment and access to new therapies.
Topics of abc7:
The 7th...
GRB2 is an adaptor protein of HER2 (and several other tyrosine kinases), which we identified as a novel BECN1 (Beclin 1) interacting partner. GRB2 co-immunoprecipitated with BECN1 in several breast cancer cell lines and regulates autophagy through a mechanism involving the modulation of the class III PI3Kinase VPS34 activity. In ovo studies in a CA...
BACKGROUND
The evaluation of electronic patient reported outcomes (ePROs) is increasingly being used in clinical studies with patients with cancer and enables structured and standardized data collection in patients’ everyday lives. So far few studies or analyses focus on the medical benefit of ePROs for patients.
OBJECTIVE
The current exploratory...
Zusammenfassung
In einem 2-jährigen Rhythmus fand in St. Gallen in früheren Jahren und nun in Wien die „St. Gallen (SG) International Breast Cancer Conference“ statt. Dieses Jahr (2023) wurde diese Konferenz, die sich mit der Behandlung von Patientinnen in Frühstadien des Mammakarzinoms beschäftigt, zum 18. Mal durchgeführt. Am Ende dieser 4-tägige...
Zusammenfassung
Eine Reihe von neuen Therapien hat in den letzten Jahren die Fortschritte in der Behandlung von Patientinnen mit fortgeschrittenem Mammakarzinom bestimmt. Diese Substanzen sind hauptsächlich die CDK4/6-Inhibitoren und weitere Substanzen, welche die endokrine Resistenz überwinden können, die oralen selektiven Östrogenrezeptor-Degradi...
The St. Gallen (SG) International Breast Cancer Conference is held every two years, previously in St. Gallen and now in Vienna. This year (2023) marks the eighteenth edition of this conference, which focuses on the treatment of patients with early-stage breast carcinoma. A panel discussion will be held at the end of this four-day event, during whic...
Purpose:
BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib.
Method...
Background:
Each year the interdisciplinary Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), German Gynecological Oncology Group Breast Committee on Diagnosis and Treatment of Breast Cancer provides updated state-of-the-art recommendations for early and metastatic breast cancer.
Summary:
The updated evidence-based treatment recommendation for...
Zusammenfassung
Die in den letzten Jahren begonnenen großen Studienprogramme zu den CDK4/6-Inhibitoren, den zielgerichteten Therapien und den Antikörper-Medikament-Konjugaten resultieren in Ergebnissen, die von aktuellen Studien auf internationalen Kongressen und Fachzeitschriften veröffentlicht werden. In diesem Zusammenhang sind neue Ergebnisse d...
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2023 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (mBC).
With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant tr...
In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summariz...
Background
Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 −) MBC, addition of targeted oral agents such as everolimus or a cycline-dependent kinase 4/6 (CDK 4/6) inhibitor (e.g., palbociclib, ribo...
The St. Gallen Consensus Conference on early breast cancer treatment 2023 was again a live event and took place in Vienna, Austria. After 4 years and one virtual event due to the pandemic, more than 2,800 participants from over 100 countries came together in Vienna, and the 2023 St. Gallen/Vienna conference was a great success. Over three days, the...
Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody–drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increa...
The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at...
Background:
In node-negative breast cancer (NNBC), a high risk of recurrence is determined by clinico-pathological or tumor-biological assessment. Taxanes may improve adjuvant chemotherapy.
Methods:
NNBC 3-Europe, the first randomized phase-3 trial in node-negative breast cancer (BC) with tumor-biological risk assessment, recruited 4146 node-neg...
Introduction: HER2-positive breast cancer is considered aggressive, but due to the development of targeted drugs in the past 20 years, a substantial improvement of therapy results can be postulated. Proven evidence is provided by data of randomized clinical trials. The present study aimed at demonstrating the improvement of therapy results over tim...
Zusammenfassung
Für die Behandlung von Patientinnen mit fortgeschrittenem HER2-negativem, hormonrezeptorpositivem Mammakarzinom sind in den letzten Jahren einige Substanzen in die Praxis eingeführt worden. Zusätzlich sind weitere Medikamente in der Entwicklung. Im letzten Jahr sind einige Studien veröffentlicht worden, die entweder einen Vorteil fü...
Zusammenfassung
Die Empfehlungen der AGO-Kommission Mamma zur operativen Therapie des Mammakarzinoms wurden zuletzt im März 2022 aktualisiert (www.ago-online.de). Da die operative Therapie einen von mehreren Teilschritten bei der Behandlung des Mammakarzinoms darstellt, sind eine umfangreiche diagnostische und onkologische Expertise eines Brustoper...
Zusammenfassung
Für Patientinnen mit einem fortgeschrittenen Mammakarzinom sind in den letzten Jahren mit den CDK4/6‑Inhibitoren, den Immuncheckpoint-Inhibitoren, den PARP-Inhibitoren, dem Alpelisib, Tucatinib und Trastuzumab-Deruxtecan sowie Sacituzumab-Govitecan einige Therapien neu etabliert worden, welche die Therapielandschaft von Patientinnen...
Zusammenfassung
In dieser Übersichtsarbeit werden neueste Entwicklungen in der Prävention von Brustkrebs und Behandlung von Patientinnen mit frühen Krankheitsstadien mit Mammakarzinom zusammengefasst. Die Ermittlung von individuellen Erkrankungsrisiken nach molekularen Subtypen wurde in einer großen epidemiologischen Studie untersucht. Im Bereich d...
Purpose
Phosphatidylinositide-3-kinase (PI3K) regulates proliferation and apoptosis; somatic PIK3CA-mutations may activate these processes. Aim of this study was to determine the prevalence of PIK3CA-mutations in a cohort of early stage breast cancer patients and the association to the course of disease.
Patients and methods
From an unselected coh...
Tumour-infiltrating lymphocytes (TILs) are considered to have prognostic and predictive value for patients with early breast cancer. We examined 1166 breast cancer patients from a prospective, multicentre cohort (Prognostic Assessment in Routine Application (PiA), n = 1270, NCT 01592825) following recommendations from the International TILs Working...
Over the past few years, there have been many developments in the treatment of advanced breast cancer; these have been incorporated into national and international treatment guidelines, resulting in an improved prognosis for these patients. The 6th International Consensus Conference for Advanced Breast Cancer (ABC6) was held in November 2021. The a...
The recommendations of the AGO Breast Committee on the surgical therapy of breast cancer were last updated in March 2022 (www.ago-online.de). Since surgical therapy is one of several partial steps in the treatment of breast cancer, extensive diagnostic and oncological expertise of a breast surgeon and good interdisciplinary cooperation with diagnos...
Zusammenfassung
Die Erkenntnisse über die Behandlung von Mammakarzinompatientinnen mit frühen Krankheitsstadien haben im letzten Jahr deutlich zugenommen. Abemaciclib, Olaparib und Pembrolizumab sind neue Medikamente mit einer guten Wirksamkeit bei den entsprechenden Patientinnengruppen. Jedoch sind einige Fragestellungen nach wie vor unbeantwortet...
For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for...
This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on...
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM50-based multigene expression test Prosigna® in a prospective multicentric study. In 119/142 cases, P...
For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer...
Evidence relating to the treatment of breast cancer patients with early-stage disease has increased significantly in the past year. Abemaciclib, olaparib, and pembrolizumab are new drugs with good efficacy in the relevant patient groups. However, some questions remain unanswered. In particular, it remains unclear which premenopausal patients with h...
Zusammenfassung
Trotz der COVID-19-Pandemie und weitgehend virtueller Kongresse schreitet die Innovation in Bezug auf die Behandlung von Patientinnen mit Mammakarzinom mit ungebremster Geschwindigkeit fort. Dieser Übersichtsartikel fasst die aktuellen Entwicklungen zusammen. Die ersten Daten zum Gesamtüberleben für eine Therapie mit einem CDK4/6-In...
Zusammenfassung
Im vergangenen Jahr wurden für viele Patientinnen mit Mammakarzinom in frühem Krankheitsstadium neue und effektive Optionen für eine weitere Verbesserung der Behandlungsergebnisse gezeigt. Für Patientinnen mit hormonrezeptorpositiver Erkrankung zeigte sich ein signifikanter Zusatzeffekt durch den Einsatz des CDK4/6-Inhibitors Abemac...
Introduction:
The AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Task Force on Diagnosis and Treatment of Breast Cancer as an interdisciplinary team consists of specialists from gynecological oncology, pathology, diagnostic radiology, medical oncology, and radiation oncology with a special focus on breast c...
The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2022 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer (MBC).
The principles of immuno-oncology treatment have different spectra of side effects. In addition to acute treatment-related adverse events (AE), which sometimes lead to termination of treatment, there are also AEs that can occur after a latent time period, even long after discontinuation of the immuno-oncology agents, for example autoimmune reaction...
The general topic of this year’s 17th St. Gallen (SG) International Consensus Conference on the treatment of patients with early breast cancer (SG-BCC) was “Customizing local and systemic therapies for women with early breast cancer.” This topic considers that each treatment decision must also consider the cancer-specific situation of the individua...
Modern systemic treatment for breast cancer is based on the tumor subtype and the individual risk of recurrence. In the case of high-risk situations chemotherapy is usually administered, sometimes combined with targeted substances and preferably in the neoadjuvant setting. Due to the neoadjuvant concept, the response to treatment can be postoperati...
Purpose: The phosphatidylinositide-3-kinase (PI3K) pathway regulates intracellular processes in relation to proliferation and apoptosis, which can be activated by somatic PIK3CA mutations. The aim of this work was to analyze the prevalence of PIK3CA mutations in an unselected cohort of patients with early stage breast cancer and their association w...
Zusammenfassung
In dieser Übersichtsarbeit werden relevante Aspekte kürzlich veröffentlichter Studien zur Behandlung von Brustkrebspatientinnen in fortgeschrittenen Stadien sowie zu Biomarkern beim Mammakarzinom zusammenfassend dargestellt und diskutiert. In den letzten Jahren wurde eine Vielzahl von Medikamenten für alle molekularen Subtypen bis z...
Zusammenfassung
Über viele Jahrzehnte war die komplette Ausräumung der axillären Lymphknoten im Sinne einer Axilladissektion ein Standardverfahren in der Therapie des Mammakarzinom. Die Zielsetzung lag in der Bestimmung des histologischen Nodalstatus für die Festlegung der adjuvanten Therapie sowie in der Sicherung der lokoregionären Tumorkontrolle...
Zusammenfassung
Kontinuierlich neue Studienergebnisse führen wiederholt zu aktualisierten Therapieempfehlungen und Leitlinien. Insbesondere beim Mammakarzinom wurden in den letzten Jahren einige Studien veröffentlicht, welche die Behandlung des frühen und fortgeschrittenen Mammakarzinoms deutlich verändert haben. Dies bedeutet jedoch nicht, dass di...
Introduction. Neoadjuvant chemotherapy (NACT) is the standard of care in aggressive breast cancer, including triple negative breast cancer (TNBC). Cytotoxic drugs specifically target proliferating cells, however, patient outcome is variable. Tumor physiology and response to therapy are orchestrated by an intricate interplay between cancer, stromal...
Introduction. Tumor cells are influenced by their microenvironment, including immune infiltration. These tumor infiltrating lymphocytes (TILs) are considered to have prognostic and predictive value for patients with early breast cancer. The aim of this study was to evaluate the distribution of TILs and the association with survival in unselected sa...
Background: Quality of life (QOL) in breast cancer patients (pts) can be greatly impacted by initial treatment and ongoing therapy, particularly if side effects and symptoms are not well tolerated. The PALLAS trial investigated whether the addition of 2 years of palbociclib (palbo) to adjuvant endocrine therapy (ET) improved invasive disease-free s...
Background. Guidelines recommend broad use of carboplatin (CBDCA) for neoadjuvant therapy (NACT) of patients with triple negative breast cancer (TNBC). However, current evidence is contradictory. The aim of this prospective observational study was to assess efficacy and feasibility of CBDCA-containing neoadjuvant therapy in clinical routine. Patien...
Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-...
This past year has seen new and effective options for further improving treatment outcome in many patients with early-stage breast cancer. Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy. In triple-negative disease, data were presented for tw...
[This corrects the article DOI: 10.1055/a-1724-9569.][This corrects the article DOI: 10.1055/a-1724-9569.].
Background:
The first International Consensus Conference for Advanced Breast Cancer (ABC1) took place 10 years ago in November 2011. The rationale was - and still is - to standardize treatment of advanced breast cancer (ABC) based on the available evidence and to ensure that worldwide all breast cancer patients receive adequate treatment and acces...
In breast cancer, the promising efficacy of farnesyltransferase inhibitors (FTIs) in preclinical studies is in contrast to only limited effects in clinical Phase II–III trials. The objective of this study was to explore the clinical relevance of farnesyltransferase β-subunit (FNTB) single nucleotide promoter polymorphisms (FNTB-173 6G > 5G (rs32157...
